Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

NCT07057310 · Enrolling by invitation

Last updated 2026-05-28

This clinical trial is testing whether GLP-1 agonists can improve physical and vascular health in postmenopausal women who are obese.

Status Enrolling by invitation Only people invited by the researchers can join.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 30 people Planned (estimated).

Who can join Ages 46–60 · female only

Timeline Started 2025-05 · est. completion 2027-03

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07057310 ↗

Description as written by the study sponsor.

In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications. The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.

Treatments tested

semaglutide or tirzepatide Drug

Semaglutide and tirzepatide will be dosed as per prescription labels
Lifestyle modification intervention Behavioral

All participants will be recommended the following: 1) low-calorie diet based on their predicted by Harris Benedict resting energy expenditure minus 500 kcal per day; 2) physical activity: a goal of 10,000 steps or more per day; 3) exercise: a goal of 150 minutes or more of moderate-intensity aerobic activity (cardiovascular exercise) per week; 4) limited consumption of liquid calories (i.e. sodas, juices, alcohol, etc.).

Main thing measured	Physical Function Measure: Short Physical Performance Battery (SPPB) score.
Sponsor	Mayo Clinic
Conditions studied	Obesity, Menopause
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07057310 ↗